/
Cardiovascular
Atrial Fibrillation
99
Pipeline Programs↗
304
Active Trials↗
81
Companies Involved↗
Atrial Fibrillation is a moderately active landscape with 99 programs across 81 companies. The most active players are Johnson & Johnson, Anthos Therapeutics, Inc., Acesion Pharma. 15 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical74
Phase 11
Phase 29
Phase 315
Approved
No programs
Analysis
Modality Breakdown
98%
Small molecule
92 of 94 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 94 classified programs, each share of the total. Modality classified for 98% of 99 pipeline programs.
Analysis
Trial Status
854
clinical trials
Completed364 · 43%
Recruiting160 · 19%
Unknown status108 · 13%
Not yet recruiting86 · 10%
Terminated59 · 7%
Active, not recruiting49 · 6%
Other28 · 3%
Clinical Trials
Trial Activity
854 trials
Page 1 of 57
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)